Wealthstream Advisors’s ADMA Biologics ADMA Stock Holding History

Wealthstream Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,000	Closed	-$36K	–	68
2022 Q2	$36K	Buy	+18,000	New	+$35.4K	0.04%	69

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Wealthstream Advisors's ADMA Position: Q3 2022 in Review

Wealthstream Advisors sold out of ADMA Biologics (ADMA) in Q3 2022, closing a stake of 18,000 shares — an estimated $36K sold.

Wealthstream Advisors first reported a position in ADMA in Q2 2022 and held it in 1 quarter. The position peaked at $36K in Q2 2022. 130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

Wealthstream Advisors reported no remaining ADMA Biologics position as of Q3 2022 after selling out during the quarter.
Wealthstream Advisors sold 18,000 ADMA Biologics shares in Q3 2022, an estimated $36K.
Wealthstream Advisors first reported a position in ADMA Biologics in Q2 2022 and held it in 1 quarter.
Wealthstream Advisors's ADMA Biologics position peaked at $36K in Q2 2022.
130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on Wealthstream Advisors's 13F filing for Q3 2022, filed 28 Oct 2022.